This document discusses multi-indication pricing (MIP), where medicines are priced differently for separate indications. The document examines the pros and cons of MIP compared to uniform pricing across all indications. It also explores international examples of MIP and whether MIP could be implemented in the UK using the Systemic Anti-cancer Therapy dataset to track drug usage by indication. While MIP may allow prices to better reflect clinical value and increase access, ensuring accurate tracking of drug usage by indication presents challenges for implementation in the UK healthcare system.